Chronic Lymphocytic Leukemia and Follicular Lymphoma | Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia and Follicular Lymphoma from the 2020 ASH Annual Meeting — Issue 1

published 5 months ago by Dr Neil Love

Featuring an interview with Dr Ann S LaCasce on the following topics: Real-world prognostic biomarker testing, treatment patterns and dosing among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL™ prospective observational registry (0:00) Outcomes with first-line ibrutinib among patients with CLL/SLL and high-risk genomic features: Integrated analysis of the RESONATE-2 and iLLUMINATE trials (3:09) Clinical outcomes among real-world patients with CLL initiating first-line ibrutinib or chemoimmunotherapy stratified by risk status: Results from a US retrospective chart review study (8:14) Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with CLL (10:31) Final results from the ASCEND trial comparing acalabrutinib to idelalisib/rituximab or bendamustine/rituximab for relapsed/refractory (R/R) CLL (12:31) Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, Phase III CLL14 trial (13:50) Enduring undetectable minimal residual disease in patients with R/R CLL after venetoclax/rituximab: Five-year analysis of the MURANO study (16:06) Efficacy of ibrutinib with venetoclax in the treatment of CLL and SLL (20:22) Acalabrutinib in combination with venetoclax and either obinutuzumab or rituximab for patients with treatment-naïve or R/R CLL (23:01) Results from the Phase I/II BRUIN study of LOXO-305, a highly selective noncovalent Bruton tyrosine kinase inhibitor, for previously treated CLL or SLL (26:45) Superiority of umbralisib with ublituximab compared to obinutuzumab with chlorambucil for patients with treatment-naïve or R/R CLL in the Phase III UNITY-CLL study (29:36) Updated results from a Phase I/II study of duvelisib and venetoclax in patients with R/R CLL/SLL or Richter’s syndrome (32:55) Lisocabtagene maraleucel alone or in combination with ibrutinib for R/R CLL or SLL on the TRANSCEND CLL 004 trial (34:34) Subgroup analyses of elderly patients aged ≥70 years in MAGNIFY: A Phase IIIb interim analysis of induction R2 followed by maintenance in R/R indolent non-Hodgkin lymphoma (NHL) (40:32) Efficacy and tolerability of tazemetostat for R/R follicular lymphoma (FL) (42:44) CITADEL-203: A Phase II study evaluating the efficacy and safety of parsaclisib in patients with R/R FL (49:11) Primary analysis of ZUMA-5: A Phase II study of axicabtagene ciloleucel for R/R indolent NHL (50:58) Efficacy and safety of tisagenlecleucel in adult patients with R/R FL: Interim analysis of the Phase II ELARA trial (52:36) Efficacy of mosunetuzumab in patients with multiple regimen-refractory FL: Updated data from a Phase I dose-escalation trial (57:19) Novel approaches under investigation for CLL and FL; management of Richter’s transformation (1:02:11) Impact of COVID-19 on the care of patients with CLL or FL (1:07:17) CME information and select publications

more episodes from Research To Practice | Oncology Videos